Serum hepatocyte growth factor as a predictor of disease severity and future exacerbations in patients with non-cystic fibrosis bronchiectasis. (August 2021)

• Record Type: Journal Article
• Authors: Jeong, Jong Hwan; Heo, Manbong; Kim, Eun Ji; Hah, Young-Sool; Heo, I Re; Kim, Tae Hoon; Kim, Ho Cheol; Ju, Sunmi; Yoo, Jung Wan; Jeong, Yi Yeong; Lee, Jong Deog; Lee, Seung Jun
• Is Part Of: Respiratory medicine. Volume 185(2021)
• Publication Date: 2021-08
• Subjects: Hepatocyte growth factor -- Pentraxin-3 -- Osteopontin -- Non-cycstic fibrosis bronchiectasis -- FACED score -- Bronchiectasis severity index -- Exacerbation; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2021.106505
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: Background: Serum biomarkers associated with the severity of non-cystic fibrosis (CF) bronchiectasis are insufficient. This study determined the association of serum hepatocyte growth factor (HGF), osteopontin, and pentraxin-3 levels with disease severity and exacerbation in patients with non-CF bronchiectasis. Methods: Serum levels of HGF, osteopontin, and pentraxin-3 were measured in patients with clinically stable non-CF bronchiectasis (n = 61). The correlation between the biomarkers and bronchiectasis severity index (BSI) and FACED score was assessed using univariate and multivariate linear regression analyses. Predictive variables associated with exacerbation were analyzed using a Cox proportional hazards model and the time to first exacerbation in high and low HGF groups during the observation period was compared using Kaplan-Meier survival curves. Results: The BSI showed significant correlation with HGF (r = 0.423; p = 0.001) and pentraxin-3 (r = 0.316; p = 0.013). The FACED score was significantly correlated with HGF (r = 0.406; p = 0.001). Univariate and multivariate linear regression analysis revealed that serum level of HGF was independently associated with both scoring systems. The high HGF group showed a significantly shorter time to first exacerbation (Log-rank test, p = 0.014). Multivariate Cox proportional hazards regression analysis revealed that high serum HGF level and colonization with non-pseudomonas organisms were independent predictors of future exacerbations (HR 2.364; p = 0.024 and HR 2.438; p = 0.020, respectively). Conclusion: Serum level of HGF is a potential biomarker that is closely associated with disease severity and future risk of exacerbations in patients with non-CF bronchiectasis. Highlights: Serum level of Hepatocyte Growth Factor (HGF) is associated with severity of non-CF bronchiectasis. Serum levels of Osteopontin and Pentraxin-3 are unlikely associated with severity of bronchiectasis. HGF level in stable status can predict acute exacerbation in bronchiectasis patients.